Hochster H, Levin M, Speyer J, Dunleavy S, Harris M, Roses D, Golomb F, Muggia F
Cancer Treat Rep. 1985 Jan;69(1):39-42.
Twenty-one patients with advanced malignant melanoma were treated with dacarbazine at a dose of 800 mg/m2 as a single infusion and dactinomycin at a dose of 1.2 mg/m2 every 3 weeks. Hematologic toxicity was mild and gastrointestinal toxicity was tolerable. The response rate for evaluable patients was 22%, which included both men and women with visceral disease. Three of the four responses were complete. Durations of response were 4, 6, 9, and 48+ months. We conclude that dacarbazine can be safely and effectively given as a single dose along with dactinomycin. The possibility that this combination may be more effective than single agents in obtaining complete responses in patients with visceral disease must be explored further.
21例晚期恶性黑色素瘤患者接受了达卡巴嗪治疗，剂量为800mg/m²，静脉单次输注，同时接受放线菌素治疗，剂量为1.2mg/m²，每3周一次。血液学毒性较轻，胃肠道毒性可耐受。可评估患者的缓解率为22%，包括患有内脏疾病的男性和女性。4例缓解中有3例为完全缓解。缓解持续时间分别为4、6、9和48 + 个月。我们得出结论，达卡巴嗪与放线菌素联合单剂量给药安全有效。这种联合用药在使内脏疾病患者获得完全缓解方面可能比单一药物更有效的可能性，必须进一步探索。
